Skip to main content

Table 4 Prospective associations of plasma tran-fatty acids with risk of cancer mortality (n = 1456)

From: Plasma trans-fatty acids levels and mortality: a cohort study based on 1999–2000 National Health and Nutrition Examination Survey (NHANES)

 

Events (n/%)

Number at risk (Person-years)

Model 1

Model 2

Model 3

 

Hazard ratio

(95% CI)

P value

Hazard ratio

(95% CI)

P value

Hazard ratio

(95% CI)

P value

Elaidic acid (C18:1 t9), μM

Per 10 units increase

60(4.1)

1456 (16034)

1.08(0.98–1.19)

0.137

1.05(0.91–1.23)

0.492

0.88(0.59–1.32)

0.549

Per sd increase

1.18(0.95–1.48)

0.137

1.13(0.80–1.58)

0.492

0.76(0.31–1.86)

0.549

Quartile (Range, μM)

 Quartile 1 (4.5–23.4)

14(3.9)

363(3974)

1.18(0.56–2.52)

0.662

1.42(0.64–3.17)

0.388

1.49(0.66–3.36)

0.336

 Quartile 2 (23.5–32.3)

13(3.6)

363(4078)

Reference

 

Reference

 

Reference

 

 Quartile 3 (32.4–44.7)

13(3.6)

366(4048)

1.29(0.60–2.81)

0.514

1.47(0.67–3.24)

0.340

1.42(0.63–3.18)

0.398

 Quartile 4 (44.9–238)

20(5.5)

364(3934)

1.86(0.92–3.75)

0.085

1.87(0.82–4.26)

0.139

1.65(0.59–4.63)

0.343

Vaccenic acid (C18:1 t11), μM

Per 10 units increase

60(4.1)

1456 (16034)

1.07(0.99–1.16)

0.093

1.07(0.94–1.21)

0.326

1.09(0.82–1.46)

0.553

Per sd increase

1.18(0.97–1.44)

0.093

1.17(0.85–1.61)

0.326

1.25(0.60–2.59)

0.553

Quartile (Range, μM)

 Quartile 1 (4.45–27.9)

12(3.3)

364(3997)

0.86(0.39–1.89)

0.708

0.83(0.36–1.91)

0.655

0.82(0.35–1.92)

0.650

 Quartile 2 (27.9–37.5)

13(3.6)

363(4019)

Reference

 

Reference

 

Reference

 

 Quartile 3 (37.6–49.7)

15(4.1)

364(4036)

1.18(0.56–2.48)

0.667

1.41(0.66–3.03)

0.374

1.46(0.66–3.25)

0.351

 Quartile 4 (49.8–313)

20(5.5)

365(3982)

1.65(0.82–3.31)

0.162

1.73(0.77–3.88)

0.184

2.03(0.68–6.03)

0.205

Palmitelaidic acid (C16:1 t9), μM

Per unit increase

60(4.1)

1456 (16034)

1.05(1.00–1.12)

0.064

1.06(0.97–1.15)

0.176

1.06(0.95–1.18)

0.314

Per sd increase

1.23(0.99–1.52)

0.064

1.25(0.91–1.71)

0.176

1.24(0.81–1.90)

0.314

Quartile (Range, μM)

 Quartile 1 (1.1–5.1)

13(3.6)

363(3989)

1.34(0.61–2.96)

0.467

1.55(0.67–3.57)

0.302

1.56(0.68–3.61)

0.295

 Quartile 2 (5.1–6.8)

12(3.3)

365(4060)

Reference

 

Reference

 

Reference

 

 Quartile 3 (6.9–9.4)

13(3.6)

364(4057)

1.00(0.46–2.20)

0.991

1.30(0.57–2.98)

0.532

1.34(0.57–3.11)

0.500

 Quartile 4 (9.4–33.1)

22(6.0)

364(3928)

1.97(0.97–3.98)

0.059

2.56(1.09–6.00)

0.031

2.91(1.09–7.81)

0.034

Linolelaidic acid (C18:2 t9, 12), μM

Per unit increase

60(4.1)

1456 (16034)

1.12(0.97–1.30)

0.128

1.07(0.85–1.35)

0.562

1.05(0.75–1.47)

0.762

Per sd increase

1.20(0.95–1.51)

0.128

1.11(0.77–1.61)

0.562

1.09(0.63–1.86)

0.762

Quartile (Range, μM)

 Quartile 1 (0.7–2.0)

14(3.8)

364(3975)

1.16(0.55–2.44)

0.694

1.50(0.68–3.28)

0.311

1.58(0.71–3.53)

0.263

 Quartile 2 (2.0–2.7)

14(3.9)

363(4004)

Reference

 

Reference

 

Reference

 

 Quartile 3 (2.7–3.7)

16(4.4)

365(4057)

1.85(0.89–3.83)

0.098

2.00(0.93–4.30)

0.077

1.97(0.90–4.33)

0.089

 Quartile 4 (3.7–13.4)

16(4.4)

364(3998)

1.61(0.78–3.33)

0.199

1.33(0.57–3.12)

0.514

1.24(0.46–3.34)

0.672

  1. Model 1: adjusted for age, gender at baseline
  2. Model 2: further adjusted for race, body mass index, systolic blood pressure, diastolic blood pressure, fasting plasma glucose, triglyceride, total cholesterol, high density lipoprotein, uric acid, estimation glomerular filtration rate, alcohol use, smoking, and self-reported cardiovascular diseases history at baseline
  3. Model 3: further adjusted for other trans-fatty acid subtypes
Back to article page

Lipids in Health and Disease

ISSN: 1476-511X